FEMSelect is making a lasting impact on women's health by delivering an innovative technology platform.
FEMSelect is making a lasting impact on women's health by delivering an innovative technology platform. It is the developer of EnPlace, a minimally invasive and mesh-free system for pelvic floor ligament fixation. Using EnPlace takes approximately 30 minutes. The patented delivery system enables the precise guidance, insertion, and deployment of the anchor unit. The anchor is designed to be introduced through the vaginal wall and secured to the pelvic floor ligament to provide stabilization.FEMSelect was founded in 2012 and is headquartered in Modi’in, Israel.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 19, 2022 | Series B | $9M | 9 | New Age Ventures Triventures | — | Detail |
Dec 4, 2020 | Convertable Note | $235K | 1 | — | — | Detail |
May 20, 2020 | Convertable Note | $560K | 1 | — | — | Detail |
Mar 13, 2018 | Series A | $3M | 1 | Mid Atlantic Bio Angels | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
New Age Ventures | Yes | Series B |
Triventures | Yes | Series B |
Keiretsu Forum Mid Atlantic | — | Series B |
Keiretsu Capital | — | Series B |
MEDA Angels | — | Series B |
Mid Atlantic Bio Angels | — | Series B |
RAD BioMed Accelerator | — | Series B |
Robin Hood Ventures | — | Series B |
TransPacific Venture Partners | — | Series B |